Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insider on the transaction. Insider, a leading AI-native omnichannel experience and customer engagement platform, announced raising $500 million in Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Redaptive on the transaction. Redaptive, a leading Energy-as-a-Service (EaaS) provider, announced it has secured an additional $100 million equity investment...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Stripe on the transaction. Financial infrastructure platform Stripe confirmed that it is acquiring stablecoin infrastructure provider Bridge. The transaction, which...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Featurespace in the deal. Visa (NYSE: V) announced it has signed a definitive agreement to acquire Featurespace, a developer of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vertos Medical Inc. on the transaction. Stryker (NYSE: SYK), a global leader in medical technologies, announced a definitive agreement to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Borealis Biosciences on the transaction. Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Astranis on the transaction. Astranis announced the completion of a $200 million Series D funding round led by long-time investor...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom LLP and Roschier advised Nokia on the transaction, and Wilson Sonsini Goodrich & Rosati advised Infinera. Nokia (NYSE: NOK) and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Boston Scientific Corporation in the transaction, and Wilson Sonsini Goodrich & Rosati represented Silk Road Medical. Boston Scientific Corporation (“Boston Scientific”) (NYSE:...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Mobile Health on the transaction, while Paul Hastings and Bass, Berry & Sims advised H.I.G. Growth Partners. H.I.G. Growth Partners...
You must be a Standard 1 Year member to access this content.
